Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.05. | DIH Holding US ändert Vereinbarung mit Investor | 17 | Investing.com Deutsch | ||
30.05. | DIH HOLDING US, INC. - 8-K, Current Report | 1 | SEC Filings | ||
12.05. | DIH HOLDING US, INC. - 8-K, Current Report | 1 | SEC Filings | ||
02.05. | DIH HOLDING US, INC. - 8-K, Current Report | 1 | SEC Filings | ||
07.04. | DIH HOLDING US, INC. - 8-K, Current Report | - | SEC Filings | ||
14.03. | DIH HOLDING US, INC. - 8-K, Current Report | 1 | SEC Filings | ||
DIH HOLDING US Aktie jetzt für 0€ handeln | |||||
03.03. | DIH HOLDING US, INC. - 8-K, Current Report | - | SEC Filings | ||
14.02. | DIH Holding US, Inc.: DIH Announces Third Quarter 2025 Financial Results | 265 | GlobeNewswire (Europe) | NORWELL, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporates visual... ► Artikel lesen | |
14.02. | DIH HOLDING US, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
13.02. | DIH HOLDING US, INC. - 8-K, Current Report | - | SEC Filings | ||
04.02. | DIH Strengthens Strategic Alliance With Zahrawi Group | - | RTTNews | ||
04.02. | DIH und Zahrawi Group erweitern Partnerschaft auf Saudi-Arabien | 1 | Investing.com Deutsch | ||
04.02. | DIH expands strategic partnership with Zahrawi Group | - | Seeking Alpha | ||
04.02. | DIH HOLDING US, INC. - 8-K, Current Report | - | SEC Filings | ||
03.02. | DIH Holding US, Inc.: DIH Announces Closing of $4.6 Million Public Offering | 1 | GlobeNewswire (USA) | ||
31.01. | DIH announces pricing of $4.6M public offering | 1 | Seeking Alpha | ||
31.01. | DIH Holding legt Preis für öffentliches Angebot bei 0,7832 US-Dollar pro Einheit fest | 2 | Investing.com Deutsch | ||
31.01. | DIH Holding US, Inc.: DIH Announces Pricing of $4.6 Million Public Offering | 2 | GlobeNewswire (USA) | ||
28.01. | DIH Holding US, Inc.: DIH Announces Strategic Partnership with Nobis Rehabilitation Partners | 205 | GlobeNewswire (Europe) | NORWELL, Mass. and ALLEN, Texas, Jan. 28, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate... ► Artikel lesen | |
28.01. | DIH HOLDING US, INC. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
PING AN HEALTHCARE | 0,946 | +1,42 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
MOUNTAIN VALLEY MD | 0,014 | -5,41 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,242 | +2,54 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
VOLITIONRX | 0,750 | -11,00 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
IMUNON | 0,665 | +4,72 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
BEYOND AIR | 0,146 | +3,55 % | Beyond Air-Aktionäre genehmigen Reverse-Aktiensplit | ||
AVINGER | 0,340 | -6,08 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
SIEMENS HEALTHINEERS | 46,900 | +0,13 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
FRESENIUS | 42,590 | +0,95 % | Aktienmarkt: Fresenius SE & Co. KGaA-Aktie kann sich nicht behaupten (42,16 €) | Der Anteilsschein von Fresenius SE & Co. KGaA notiert am Mittwoch leichter. Die Aktie kostete zuletzt 42,16 Euro. Für Inhaber von Fresenius+Co KgaA ist der heutige Handelstag bisher nicht sonderlich... ► Artikel lesen |